Halozyme Therapeutics, Inc.HALONASDAQ
Loading
EV to Sales: Discounted ValuationCompressed
Percentile Rank0
3Y CAGR-25.5%
5Y CAGR-24.2%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
-25.5%/yr
vs -1.0%/yr prior
5Y CAGR
-24.2%/yr
Consistent
Acceleration
-24.5pp
Decelerating
Percentile
P0
Near historical low
vs 5Y Ago
0.3x
Contraction
Streak
5 yr
Consecutive declineCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 5.68 | -22.6% |
| 2024 | 7.34 | -2.7% |
| 2023 | 7.55 | -45.0% |
| 2022 | 13.72 | -5.1% |
| 2021 | 14.47 | -36.2% |
| 2020 | 22.67 | +56.4% |
| 2019 | 14.50 | +1.6% |
| 2018 | 14.27 | +61.5% |
| 2017 | 8.84 | -7.8% |
| 2016 | 9.59 | - |